RELIZORB
Device
ALCRESTA THERAPEUTICS, INC.
Total Payments
$3.1M
Transactions
2,644
Doctors
1,370
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $170,172 | 869 | 555 |
| 2023 | $321,953 | 844 | 604 |
| 2022 | $1.3M | 299 | 185 |
| 2021 | $314,974 | 43 | 22 |
| 2020 | $84,543 | 45 | 12 |
| 2019 | $221,338 | 261 | 134 |
| 2018 | $331,423 | 168 | 108 |
| 2017 | $399,953 | 115 | 33 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 46 | 43.0% |
| Consulting Fee | $769,760 | 58 | 24.5% |
| Current or prospective ownership or investment interest | $332,034 | 2 | 10.6% |
| Honoraria | $174,801 | 71 | 5.6% |
| Space rental or facility fees (teaching hospital only) | $120,498 | 68 | 3.8% |
| Food and Beverage | $110,936 | 2,130 | 3.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $95,500 | 38 | 3.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $94,250 | 35 | 3.0% |
| Travel and Lodging | $55,531 | 182 | 1.8% |
| Grant | $13,020 | 2 | 0.4% |
| Education | $11,768 | 9 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,250 | 3 | 0.4% |
Payments by Type
General
$1.8M
2,598 transactions
Research
$1.4M
46 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 90 Day Observational Study as an Extension to the Phase 3, Open Labeled, Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition | ALCRESTA THERAPEUTICS, INC. | $624,668 | 0 |
| General Research relating to application of RELiZORB technology in various patient populations | ALCRESTA THERAPEUTICS, INC. | $348,471 | 0 |
| Clinical Trial titled Absorption and Safety With Sustained Use of Relizorb Evaluation (ASSURE) Study | ALCRESTA THERAPEUTICS, INC. | $161,109 | 0 |
| Fat Absorption from Enteral Formula Through an In-Line Digestive Cartridge in a Piglet Model of Short Bowel Syndrome | ALCRESTA THERAPEUTICS, INC. | $111,534 | 0 |
| Retrospective Review of Relizorb Use in Patients with Severe Pancreatitis | ALCRESTA THERAPEUTICS, INC. | $47,600 | 0 |
| IRB-P0042824 | Alcresta Therapeutics, Inc. | $35,750 | 0 |
| Utilization of the inline digestive cartridge RELiZORB in a surgical intensive care unit | ALCRESTA THERAPEUTICS, INC. | $23,000 | 0 |
Top Doctors Receiving Payments for RELIZORB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $1.7M | 134 |
| , M.D | Internal Medicine | Libertyville, IL | $442,145 | 9 |
| , M.D | Pediatrics | Darien, CT | $366,434 | 6 |
| , M.D | Anesthesiology | Boston, MA | $78,423 | 84 |
| , M.D | Pediatric Surgery | Boston, MA | $56,465 | 2 |
| , M.D | Surgical Critical Care | Mansfield, OH | $50,690 | 50 |
| , M.D | Pediatric Gastroenterology | Houston, TX | $47,340 | 47 |
| , M.D | Pediatric Gastroenterology | Chicago, IL | $46,851 | 51 |
| , MB BCH MD MCH PHD FR | Surgery | Cleveland, OH | $39,824 | 28 |
| , MD | Gynecology | Carlisle, PA | $30,453 | 24 |
| , D.O | Pediatric Gastroenterology | Charleston, SC | $23,945 | 25 |
| , M.D | Surgery | New York, NY | $19,784 | 32 |
| , MD | Internal Medicine | Berkeley, CA | $19,233 | 6 |
| , M.D | Student in an Organized Health Care Education/Training Program | Dallas, TX | $17,698 | 14 |
| , MD | Surgery | Tampa, FL | $16,434 | 13 |
| , M.D | Pediatrics | San Diego, CA | $15,260 | 10 |
| Akash Pandey | Pediatric Gastroenterology | Orlando, FL | $15,034 | 13 |
| , M.D | Gastroenterology | Boston, MA | $11,235 | 31 |
| , MD | Pediatric Pulmonology | Indianapolis, IN | $10,682 | 11 |
| , M.D | Pediatrics | St Louis, MO | $10,625 | 2 |
| , M.D | Pediatric Gastroenterology | New York, NY | $8,544 | 11 |
| , MD | Neonatal-Perinatal Medicine | Cincinnati, OH | $7,839 | 7 |
| , M.D | Pediatrics | Philadelphia, PA | $7,500 | 2 |
| , MD | Internal Medicine | Rapid City, SD | $5,000 | 2 |
| , DO | Pediatric Gastroenterology | Phoenix, AZ | $4,464 | 5 |
Ad
Manufacturing Companies
- ALCRESTA THERAPEUTICS, INC. $2.5M
- Alcresta Therapeutics, Inc. $646,048
Product Information
- Type Device
- Total Payments $3.1M
- Total Doctors 1,370
- Transactions 2,644
About RELIZORB
RELIZORB is a device associated with $3.1M in payments to 1,370 healthcare providers, recorded across 2,644 transactions in the CMS Open Payments database. The primary manufacturer is ALCRESTA THERAPEUTICS, INC..
Payment data is available from 2017 to 2024. In 2024, $170,172 was paid across 869 transactions to 555 doctors.
The most common payment nature for RELIZORB is "Unspecified" ($1.4M, 43.0% of total).
RELIZORB is associated with 7 research studies, including "A 90 Day Observational Study as an Extension to the Phase 3, Open Labeled, Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition" ($624,668).